A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

This real-world study is observing how well a combination of immunotherapy (atezolizumab) and chemotherapy works before surgery for people with lung cancer. It tracks how patients do in everyday clinical settings rather than a controlled lab environment. **You may be eligible if...** - You are 18 years or older - You have been newly diagnosed with non-small cell lung cancer (NSCLC) at stage II, IIIA, or IIIB that can potentially be removed with surgery - You have not received any prior treatment for this cancer - A thoracic surgeon has confirmed your cancer is surgically removable **You may NOT be eligible if...** - You have already received chemotherapy, immunotherapy, or other cancer treatments - Your cancer is not surgically removable - You have not provided informed consent Talk to your doctor to see if this trial is right for you.